The Psoriasis Treatment Center of Central New Jersey
Welcome,         Profile    Billing    Logout  
 3 Trials 
10 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Bagel, Jerry
NCT06745999: Cryotherapy in Combination with Red Light PDT for Actinic Keratosis of Full Face

Recruiting
4
40
US
Ameluz 10% Topical Gel, ALA gel, Red Light PDT, Cryotherapy
Psoriasis Treatment Center of Central New Jersey, Biofrontera Bioscience GmbH
Actinic Keratoses
05/25
06/25
NCT05285839: Dupixent and Narrowband UVB for Atopic Dermatitis

Recruiting
4
40
US
Dupixent
Psoriasis Treatment Center of Central New Jersey, Regeneron Pharmaceuticals
Atopic Dermatitis
12/24
12/24
NCT06773403: Upadacitinib for Prurigo Nodularis

Recruiting
4
25
US
Upadacitinib
Psoriasis Treatment Center of Central New Jersey, AbbVie
Prurigo Nodularis
12/25
01/26
NCT06336343: Bimekizumab in Plaque Psoriasis

Recruiting
4
60
US
Bimekizumab
Icahn School of Medicine at Mount Sinai, UCB Pharma, Psoriasis Treatment Center of Central New Jersey
Plaque Psoriasis
10/25
10/25
ADapt, NCT05369403: A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab

Active, not recruiting
3
120
US
Lebrikizumab, LY3650150, DRM06
Eli Lilly and Company
Atopic Dermatitis
01/24
02/25
TAK-279-PsO-3003, NCT06550076: A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

Recruiting
3
1300
Europe, Canada, Japan, US, RoW
TAK-279
Takeda
Plaque Psoriasis
05/26
05/26
TOGETHER-PsO, NCT06588283: Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight

Recruiting
3
250
US
Ixekizumab, LY2439821, Tirzepatide, LY3298176
Eli Lilly and Company
Psoriasis, Obesity
12/25
05/26
TAK-279-3002, NCT06108544: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period

Active, not recruiting
3
1108
Europe, Canada, US, RoW
TAK-279, Placebo, Apremilast
Takeda
Plaque Psoriasis
12/24
11/25
NCT06176768: A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis

Recruiting
2
75
US
LY3972406, Placebo
Eli Lilly and Company
Plaque Psoriasis
04/25
07/25
TARGET-DERM, NCT03661866: A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC

Recruiting
N/A
15000
Europe, Canada, US
Target PharmaSolutions, Inc.
Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa, Vitiligo, Psoriasis, Chronic Spontaneous Urticaria
12/50
12/50

Download Options